Beyond Weight Loss: How GLP-1 Agonists Influence Gut Bioenergetics and the Host Capacity Model — The Interplay With the Host Capacity Model

The available evidence suggests an interesting alignment between GLP-1 signaling and the upstream lesion the Host Capacity Model identifies. By supporting colonocyte mitochondrial function and influencing both the microbial community and barrier integrity, GLP-1 agonists may interact with the same node the framework treats as central. This does not make them a standalone solution. It does suggest that their mechanism of action may extend beyond the metabolic axis they were designed for, and that this extended profile is worth understanding when reading complex chronic cases in patients who are already taking these medications or considering them with their clinical team.